BofA Securities Reiterates Buy Rating on Ascendis Pharma (ASND)

June 12, 2024 5:58 AM EDT Send to a Friend
BofA Securities analyst Tazeen Ahmad reiterated a Buy rating and $165.00 price target on Ascendis Pharma (NASDAQ: ASND)The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login